Kling Biotherapeutics

Kling Biotherapeutics is a clinical-stage, privately held biotech company focused on discovery and development of antibody based therapeutics. The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells. Kling-Select relies on a fully-owned and well-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralising antibodies for various infectious diseases such as RSV (Nirsevimab/Beyfortus), Covid, and Influenza....

Cancer therapeutics,infectious diseases therapeutics

Kling biotherapeutics operates in the Biotechnology research industry.

Kling biotherapeutics's revenue is 11m - 100m

Kling biotherapeutics has 11 - 50 employees.